In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series DD round generates $200mm for Intarcia

Executive Summary

Intarcia Therapeutics Inc. (drug delivery) raised an impressive $200mm in a Series DD equity financing led by first-time backer RA Capital, which was joined by new and current shareholders including Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, and three returning institutional investors. The new money will support Phase III trials of Intarcia’s Type II diabetes compound ITCA650. The company anticipates filing for regulatory approval in late 2015 or early 2016. In November 2012, it closed a $210mm round, one of the largest private biotech financings in more than two decades.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies